feed,title,long_url,short_url
InsiderMonkey,RBC Capital Remains Bullish on Viridian Therapeutics (VRDN) Following Q3 2025 Results,https://insidermonkey.com/blog/--1646424,
InsiderMonkey,UroGen Pharma (URGN) Closes Q3 2025 With $127.4 Million in Cash Amid Rising R&D Costs,https://insidermonkey.com/blog/--1646425,
InsiderMonkey,"Raymond James Remains Bullish on Liquidia (LQDA), Cites YUTREPIA’s 75% Growth in U.S. Prostacyclin Revenue",https://insidermonkey.com/blog/--1646426,
InsiderMonkey,Edgewise Therapeutics (EWTX) Reports Heightened R&D Activity in Q3 2025,https://insidermonkey.com/blog/--1646427,
InsiderMonkey,"BMO Capital Remains Bullish on Structure Therapeutics (GPCR), Cites Upcoming Trial Readouts",https://insidermonkey.com/blog/--1646428,
InsiderMonkey,"H.C. Wainwright Maintains Its Bullish Stance on Vera Therapeutics (VERA), Sees Strong Future Revenue Growth",https://insidermonkey.com/blog/--1646429,
InsiderMonkey,Jones Trading Remains Bullish on Janux Therapeutics (JANX) Amid Promising Developments in Prostate Cancer Program,https://insidermonkey.com/blog/--1646431,
InsiderMonkey,Jefferies Maintains “Buy” Rating on Wave Life Sciences (WVE) Amid Its Improving Competitive Positioning,https://insidermonkey.com/blog/--1646432,
InsiderMonkey,"William Blair Maintains Bullish Stance on Biohaven (BHVN), Sees Robust Operational Growth",https://insidermonkey.com/blog/--1646433,
InsiderMonkey,"JPMorgan Reduces PT on Syndax Pharmaceuticals (SNDX) to $33, Maintains “Overweight” Rating",https://insidermonkey.com/blog/--1646430,
